Primary Progressive Multiple Sclerosis Treatment Market (Drug Type: Approved Drugs and Pipeline Drugs; and Distribution Channel: Retail Pharmacies, E-commerce, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Primary Progressive Multiple Sclerosis Treatment Market (Drug Type: Approved Drugs and Pipeline Drugs; and Distribution Channel: Retail Pharmacies, E-commerce, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Primary Progressive Multiple Sclerosis Treatment Market – Scope of Report
TMR’s report on the global primary progressive multiple sclerosis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global primary progressive multiple sclerosis treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global primary progressive multiple sclerosis treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the primary progressive multiple sclerosis treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global primary progressive multiple sclerosis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global primary progressive multiple sclerosis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global primary progressive multiple sclerosis treatment market.

The report delves into the competitive landscape of the global primary progressive multiple sclerosis treatment market. Key players operating in the global primary progressive multiple sclerosis treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global primary progressive multiple sclerosis treatment market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market primary progressive multiple sclerosis treatment.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Primary Progressive Multiple Sclerosis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, 2017 - 2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. Key Product/Brand Analysis
5.5. Major Research Institutes Involved
5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2017 - 2031
6.3.1. Approved Drugs
6.3.2. Pipeline Drugs
6.4. Market Attractiveness By Drug Type
7. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast By Distribution Channel, 2017 - 2031
7.3.1. Retail Pharmacies
7.3.2. E-commerce
7.3.3. Others
7.4. Market Attractiveness By Distribution Channel
8. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Country/Region
9. North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Drug Type, 2017 - 2031
9.2.1. Approved Drugs
9.2.2. Pipeline Drugs
9.3. Market Value Forecast By Distribution Channel, 2017 - 2031
9.3.1. Retail Pharmacies
9.3.2. E-commerce
9.3.3. Others
9.4. Market Value Forecast By Country, 2017 - 2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Drug Type, 2017 - 2031
10.2.1. Approved Drugs
10.2.2. Pipeline Drugs
10.3. Market Value Forecast By Distribution Channel, 2017 - 2031
10.3.1. Retail Pharmacies
10.3.2. E-commerce
10.3.3. Others
10.4. Market Value Forecast By Country, 2017 - 2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country
11. Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Type, 2017 - 2031
11.2.1. Approved Drugs
11.2.2. Pipeline Drugs
11.3. Market Value Forecast By Distribution Channel, 2017 - 2031
11.3.1. Retail Pharmacies
11.3.2. E-commerce
11.3.3. Others
11.4. Market Value Forecast By Country, 2017 - 2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country
12. Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2017 - 2031
12.2.1. Approved Drugs
12.2.2. Pipeline Drugs
12.3. Market Value Forecast By Distribution Channel, 2017 - 2031
12.3.1. Retail Pharmacies
12.3.2. E-commerce
12.3.3. Others
12.4. Market Value Forecast By Country, 2017 - 2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country
13. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2017 - 2031
13.2.1. Approved Drugs
13.2.2. Pipeline Drugs
13.3. Market Value Forecast By Distribution Channel, 2017 - 2031
13.3.1. Retail Pharmacies
13.3.2. E-commerce
13.3.3. Others
13.4. Market Value Forecast By Country, 2017 - 2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis By Company (2021)
14.3. Company Profiles
14.3.1. F. Hoffmann-La Roche Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Sanofi
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Mapi Pharma Ltd.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Atara Biotherapeutics
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Takeda Pharmaceuticals International, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. AB Science
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Mallinckrodt
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings